-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $94

Benzinga·12/09/2025 15:29:50
Listen to the news
Evercore ISI Group analyst Gavin Clark-Gartner maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $89 to $94.